Investors and Media
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference
May 5, 2022
EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the 2022 Bank of America Healthcare Conference on Tuesday, May 10th. Details of the fireside chat are as follows:
Event: BofA Securities 2022 Healthcare Conference
Date & Time: Tuesday, May 10, 2022 at 8:40 a.m. PT
A live audio webcast of the presentation will be available by visiting the “Investors & Media” section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.
About 4DMT
4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT seeks to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent targeted and evolved vectors for use in our products. The company is initially focused on five clinical-stage products in three therapeutic areas for both rare and large market diseases: ophthalmology, cardiology (including Fabry disease) and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered at relatively low doses through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The five 4DMT product candidates in clinical development are: 4D-310 for Fabry disease, 4D-150 for wet AMD, 4D-125 for XLRP, 4D-110 for choroideremia and 4D-710 for cystic fibrosis.
Contacts:
Media:
Ingrid Mezo
Canale Communications
ingrid.mezo@canalecomm.com
Investors:
Mike Zanoni
VP, Investor Relations
mzanoni@4dmt.com
